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Since Venezuelan equine encephalitis virus (VEEV)
was isolated in Peru in 1942, >70 isolates have been
obtained from mosquitoes, humans, and sylvatic mammals
primarily in the Amazon region. To investigate genetic rela-
tionships among the Peru VEEV isolates and between the
Peru isolates and other VEEV strains, a fragment of the
PE2 gene was amplified and analyzed by single-stranded
conformation polymorphism. Representatives of seven
genotypes underwent sequencing and phylogenetic analy-
sis. The results identified four VEE complex lineages that
cocirculate in the Amazon region: subtypes ID (Panama
and Colombia/Venezuela genotypes), IIIC, and a new, pro-
posed subtype IIID, which was isolated from a febrile
human, mosquitoes, and spiny rats. Both ID lineages and
the IIID subtype are associated with febrile human illness.
Most of the subtype ID isolates belonged to the Panama
genotype, but the Colombia/Venezuela genotype, which is
phylogenetically related to epizootic strains, also continues
to circulate in the Amazon basin. 
V
enezuelan equine encephalitis virus (VEEV) is an
emerging mosquito-borne RNA virus in the family
Togaviridae, genus Alphavirus. Since its isolation in 1938,
many equine epizootics and epidemics have been reported
in Colombia, Venezuela, Trinidad, Peru, Ecuador, Mexico,
and the United States, and other countries (1–5); the num-
ber of reports of human and equine cases have increased
during recent years (6–8). At least 13 distinct subtypes and
varieties, including several different species, make up the
VEE complex (Table 1). Only subtype I varieties A, B, and
C have caused major outbreaks involving hundreds of
thousands of equine and human cases. Subtypes II through
VI and subtype I varieties D, E, and F are enzootic, equine-
avirulent strains not associated with major equine out-
breaks or epidemics, although they do cause human illness,
which can be fatal (9,10). 
In Peru, VEEV was first isolated in the 1940s, when
subtype IAB strains caused equine epizootics and epi-
demics along the Pacific coast (7,8). Field investigations
were later conducted to determine the origin of the IAB
strains. Initial ecologic studies in the Amazon region of
northeastern Peru (11,12) yielded 11 VEE complex isolates
from mosquitoes and sentinel hamsters during 1970 and
1971 in Quistococha, near Iquitos (Figure 1). Antigenic
analyses identified 10 isolates as subtype ID VEEV (11)
and one strain as subtype IIIC in the VEE complex (12,13).
Because these viruses were isolated only from sentinel
hamsters and mosquitoes, whether they were human
pathogens remained unclear. Not until 1993 through 1995,
when VEEV subtype ID was isolated from persons with
febrile illness in the Amazon region of Peru (4,14), was
there clear evidence that VEEV causes human disease in
this region. Two subtype ID strains were isolated from
patients in Pantoja in 1994, and 10 other subtype ID strains
were obtained from febrile patients in and around the city
of Iquitos from 1993 to 1995.
Nucleotide sequences and phylogenetic analyses
recently performed on Peruvian VEEV isolates indicated
that the 1970s VEEV subtype ID mosquito isolates and the
1994 Pantoja human isolates belong to the Colombia/
Venezuela ID genotype, whereas the 1993–1995 Iquitos
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Northern University, Ada, Ohio.human isolates belonged to the Panama ID genotype (9).
Lack of detection of the Colombia/Venezuela genotype in
the Iquitos area during 1993 through 1995, when the
Panama genotype was repeatedly isolated, suggested that
the Colombia/Venezuela genotype had been replaced by
virus strains from Panama. Because the Colombia/
Venezuela VEEV genotype is believed to give rise to epi-
zootic viruses through mutations of the E2 envelope
glycoprotein (15–18), disappearance of this genotype from
the Iquitos area could have important public health
implications.
Since 1995, 75 VEEV strains have been isolated from
mosquitoes, humans, and sentinel hamsters in Peru. We
determined the genetic relationships among strains isolat-
ed from 1995 through 2002 and compared them with other
VEEV strains isolated from the Americas. Our results indi-
cate that the VEEV subtype ID Colombia/Venezuela geno-
type continues to circulate in Iquitos but may infect people
at a lower rate than the Panama genotype. We also demon-
strated that a recent subtype III isolate is genetically dis-
tinct from the subtype IIIC strain isolated in 1971 (12).
This strain, which we propose as subtype IIID in the VEE
complex, and both subtype ID genotypes cause human
febrile disease in the Iquitos area. 
Methods
Study Sites
VEEV isolates were obtained from several locations in
Peru. The main study site was centered around Iquitos, a
city of 300,000 people on the Amazon River in the
Department of Loreto (Figure 1). The major occupations
of the inhabitants are housekeeping, teaching, military
work, agriculture, fishing, and tourism. The climate is
tropical, with a mean annual temperature of 27.5°C and
mean annual precipitation of 2.7 m (4).
Virus Isolates
The VEE complex isolates included in this study are
shown in Table 2. These viruses were provided by the
University of Texas Medical Branch World Health
Organization Collaborating Reference Center for
Arboviruses, the United States Army Medical Research
Institute of Infectious Diseases, and the U.S. Naval
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Table 1. Classification of the Venezuelan equine encephalitis (VEEV) complex of alphaviruses  





b  Location  Vector 
I  AB  VEEV  Epizootic  Virulent  Central, South, North America  Mammalophilic mosquitoes 
  C  VEEV  Epizootic  Virulent  South America  Mammalophilic mosquitoes 
  D  VEEV  Enzootic  Avirulent  Central, South America  Culex (Mel.) ocossa, panocossa, 
pedroi, adamesi, vomerifer 
  E  VEEV  Enzootic  Variable  Central America, Mexico  Cx. (Mel.) taeniopus 
  F  Mosso das Pedras  Enzootic  Unknown  Brazil  Unknown 
II    Everglades  Enzootic  Avirulent  Southern Florida  Cx (Mel.) cedecei 
III  A  Mucambo  Enzootic  Avirulent  South America  Cx (Mel.) portesi 
  B  Tonate  Enzootic  Unknown  South, North America  Unknown (Tonate), bug (Bijou 
Bridge strains from N. America) 
  C    Enzootic  Unknown  Peru  Unknown 
IV    Pixuna  Enzootic  Unknown  Brazil  Unknown 
V    Cabassou V  Enzootic  Unknown  French Guiana  Unknown 
VI    Rio Negro  Enzootic  Unknown  Argentina  Unknown 
aSource: The Arboviruses: Epidemiology and Ecology (9). 
bVirulent strains produce high viremia titers and generally >50% death rates in horses experimentally infected. 
Figure 1. Map of Peru showing the geographic distribution of the
Venezuelan equine encephalitis virus (VEEV) complex isolates
included in the study. Numbers in parenthesis indicate the number
of isolates compared to the total number of febrile cases during the
year. ID, IAB, IIIC, IIID correspond to VEEV subtypes isolated dur-
ing the indicated year.RESEARCH
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Table 2. Venezuelan equine encephalitis complex virus isolates included in this study 
Subtype  Code  Location  Year  Host  Signs and symptoms
a 
ID  IQT0988  Sanidad EP/Vargas Guerra, Iquitos  1993  Human  F, A 
ID  IQT1015  Sanidad EP/Vargas Guerra, Iquitos  1993  Human  F, H, C 
ID  IQT1026  Sanidad EP/Vargas Guerra, Iquitos  1994  Human  F, H, E, B, D, C, G, N, S 
ID  DEI5191  Pantoja, Iquitos  1994  Human  F, C, H, B 
ID  DEI5193  Pantoja, Iquitos  1994  Human  F, C, I, H, B, N, V 
ID  IQT1042  Dir. Reg Salud de Loreto, Iquitos  1994  Human  F, H, B, V 
ID  IQT1071  Pedrelor, Iquitos  1994  Human  F, H, B, E, A, I, C 
ID  IQT1081  Pedrelor, Iquitos  1994  Human  F, H, B, E, D, R, C 
ID  IQT1085  Hospital Regional Amazonas, Iquitos  1994  Human  F, H, B, D, G, N, S 
ID  IQT1098  Sanidad EP/Vargas Guerra, Iquitos  1994  Human  F, H, E, B, D, C, S 
ID  IQT1101  Pedrelor, Iquitos  1994  Human  F, H, E, B, D, V, C, G 
ID  IQT1120  Sanidad EP/Vargas Guerra, Iquitos  1994  Human  F, H, B, D, V, C 
ID  IQT1724  Pedrelor, Iquitos  1995  Human  F, H, E, B, D, V, C, I, G 
ID  IQT1735  Pedrelor, Iquitos  1995  Human  F, H, B, E, D, R, V, C 
ID  IQT3745  Sanidad EP/Vargas Guerra, Iquitos  1997  Human  F, H, E, B, D, G 
ID  IQT3971  San Antonio, Iquitos  1997  Human  F, H, E, B, D, V, I, C 
ID  IQT4091  Bellavista, Iquitos  1997  Human  F, B, D, V, I, M, V, S, J 
ID  IQT4177  Sanidad EP/Vargas Guerra, Iquitos  1997  Human  F, H, E, B, D, V, C, G 
ID  IQT4191  Bellavista, Iquitos  1997  Human  F, H, E, B, D, C, S 
ID  PC28  Iquitos  1997  Rodent (Proechimys spp.)   
III  PC254  Iquitos  1997  Rodent (Proechimys spp.)   
III  PC256  Iquitos  1997  Rodent (Proechimys spp.)   
ID  IQT5798  San Juan, Iquitos  1998  Human  F, H, E, B, D, C 
ID  IQT5831  Cardoso, Iquitos  1998  Human  F, H, E, B, D, C 
ID  IQT5876  San Juan, Iquitos  1998  Human  F, H, E, B, D, V, C 
ID  IQT5885  Moronacocha Iquitos  1998  Human  F, H, E, B, D, V, G, T 
ID  IQT6088  9 de Octubre, Iquitos  1998  Human  F, H, E, B, D, V, I, C, G 
ID  IQT6119  San Juan, Iquitos  1998  Human  F, H, E, B, D, R, V, I, C 
ID  IQT6415  San Juan, Iquitos  1998  Human  F, H, E, B, D, V, I, C 
ID  IQT6486  9 de Octubre, Iquitos  1998  Human  F, H, E, B, D, V 
ID  IQT6674  Tupac Amaru, Iquitos  1998  Human  F, H, E, B, D, C 
ID  IQT6712  Hospital Apoyo, Iquitos  1998  Human  F, H, E, B, D, V, S 
ID  IQT6937  NMRCD, Iquitos  1998  Human  F, H, E, B, D, V, S 
ID  IQT7057  San Juan, Iquitos  1998  Human  F, H, E, D, V, C 
ID  IQT7060  San Juan, Iquitos  1998  Human  F, H, E, B, D, C 
ID  IQT7327  Tupac Amaru, Iquitos  1998  Human  F, H, E, B, D, V, C, G 
ID  IQT7460  CIA Petrolera, Iquitos  1998  Human  F, H, B, C 
ID  IQT7988  Belen, Iquitos  1998  Human  F, H, B, D, V, C, G, S 
ID  IQT8131  Belen, Iquitos  1998  Human  F, H, E, B, D, R, V, C, D 
ID  IQT8558  San Juan, Iquitos  1998  Human  F, H, B, D, V, I, C, G 
ID  PE30609  Iquitos  1998  Mosquito   
III  PE407660  Iquitos  1998  Mosquito   
III  PE409040  Iquitos  1998  Mosquito   
III  PE409100  Iquitos  1998  Mosquito   
ID  IQU0465  San Antonio, Iquitos  1999  Human  F, H, E, B, D, R, C 
ID  IQU0664  San Antonio, Iquitos  1999  Human  F, H, E, B, D, C 
ID  IQU0890  6 de octubre, Iquitos  1999  Human  F, H, B, E, D, V, C 
ID  IQU0953  6 de octubre, Iquitos  1999  Human  F, H, B, E, C 
ID  IQU1050  Belen, Iquitos  1999  Human  F, H, B, E, V, C 
ID  IQU1106  San Antonio, Iquitos  1999  Human  F, H, E, B, A, V, C 
ID  IQU1217  Belen, Iquitos  1999  Human  F, H, E, B, D, V, I, C, G 
ID  IQU1279  Belen, Iquitos  1999  Human  F, H, E, B, V, C, G 
ID  IQU1282  Cardozo, Iquitos  1999  Human  F, H, E, B, D, C 
ID  IQU1318  Tupac Amaru, Iquitos  1999  Human  F, H, E, B, D, V, C 
ID  IQU1341  Zungarococha, Iquitos  1999  Human  F, H, E, B, D, R, V, C 
ID  IQU1402  Cardozo, Iquitos  1999  Human  F, H, E, B, A, V, C, G, S 
ID  IQU1718  San Antonio, Iquitos  1999  Human  F, H, E, B, D, I, C 
III  FSL0190  San Juan, Iquitos  2000  Human  F, C, L 
ID  FSL0201  San Juan, Iquitos  2000  Human  F, C, L, D, B, A 
ID  FSL0205  San Juan, Iquitos  2000  Human  F, C, L, D, B, A 
ID  FSL0240  San Juan, Iquitos  2000  Human  F, C, L, D, A, I, V, J, G 
ID  FSL0252  San Juan, Iquitos  2000  Human  F, C, L, D, B, A 
ID  IQU3026  Hospital Apoyo, Iquitos  2000  Human  F, H, E, B, D, V, C, S 
ID  FSL0507  Hospital Militar, Iquitos  2001  Human  F, H 
IIIC  54-001  Iquitos  2002  Hamster   
aA, abdominal pain; H, headache; F, fever; C, chills; E, eye pain; B, body pain; D, arthralgia; G, cough; N, nasal congestion; S, sore throat; I, 
diarrhea; V, vomits; R, rash; M, melena; J, jaundice; T, hematuria; L, malaise. Medical Research Center Detachment, Lima, Peru
(NMRCD). Most of the viruses were isolated in Vero cells
from serum samples of febrile patients, sentinel hamsters,
and mosquitoes. These viruses were passaged once in Vero
cells, and supernatant fluid was stored at –70°C for subse-
quent extraction of viral RNA.
Extraction of Viral RNA and cDNA Synthesis
Viral RNA was extracted from cell culture media as
described elsewhere (19). Briefly, 250 µL of infected cell
culture supernatant was mixed with 750 µL of Trizol LS
(Gibco BRL, Bethesda, MD), and RNA was extracted fol-
lowing the manufacturer’s protocol. For cDNA synthesis,
5 µL of the extracted RNA was mixed with 1 µmol of
reverse primer V9207B (Table 3), 1x First Strand Buffer
(Gibco BRL, Bethesda, MD), 1 mmol deoxynocleoside
triphosphate (dNTPs), 80U RNAsin (Promega, Madison,
WI), and 200 U SuperScript II Reverse Transcriptase
(Gibco BRL, Bethesda, MD), and then incubated at 42°C
for 1 h. 
PCR Amplification
Primers used for the polymerase chain reaction (PCR)
and sequencing are listed in Table 3. For amplification of
the N-terminus of the PE2 envelope glycoprotein precur-
sor gene, primers V8369(+) and V9207B(–) were used,
and the resulting product was sequenced with primers
V8659(+) and V8953(–) (19). PCRs included 2.5 U of Taq
polymerase (Promega, Madison, WI), 1X Promega Taq
buffer, 300 nmol of each primer, 1 mmol MgCl2, 0.2 mmol
dNTPs, and 10 µL of the cDNA reaction; 30 amplification
cycles included heat-denaturation at 95°C for 30 s, primer
annealing at 48°C for 30 s, and extension at 72°C for 1
min. A final extension of 10 min was used to ensure com-
plete double-stranded DNA synthesis. In the case of the
proposed subtype IIID strains, the reverse primer used for
cDNA synthesis and PCR was V9257B(–). In some cases,
PE2 amplicons were not obtained, and those isolates were
amplified by using alphavirus-specific nsP1 primers
described previously (20). The complete 26S gene of one
subtype IIID strain (human isolate FSL190) was amplified
and sequenced for further comparison with other VEE
complex subtypes; two overlapping PCR amplicons were
obtained by using primer pairs E/V 7514(+)/VIIID 10471
(–), and α10247A(+)/Mlu-T25(–), and sequenced by gene
walking. 
Single-Stranded Conformation Polymorphism (SSCP)
SSCP analysis was performed as previously described
(16). PCR products were purified with the Qiaquick gel
extraction kit (Qiagen, Valencia, CA), and 2 µLof the puri-
fied PCR amplicon DNA was mixed with 8 µL of SSCP
loading buffer (95% formamide, 0.05% bromophenol blue,
0.05% xylene cyanol). To denature the DNA, the reaction
was heated to 95°C for 5 min and immediately cooled on
ice, loaded onto an 8% polyacrylamide gel, and elec-
trophoresed in 1 x Tris-borate-EDTA buffer at room tem-
perature for 20 h at 8 mA. The single-stranded DNA
products were visualized with silver staining (21). Single-
strand conformational polymorphism genotypes were
determined by comparing the migration patterns of the
double-stranded DNA of the various isolates with one
another and against a standard DNAladder. Unique migra-
tion patterns were designated as distinct SSCP genotypes.
Sequencing and Phylogenetic Analysis
Two or three representatives of each SSCP genotype
were selected randomly for sequencing and phylogenetic
analysis. Most PCR products were sequenced directly with
an Applied Biosystems (Foster City, CA) Prism automated
DNA sequencing kit according to the manufacturer’s pro-
tocol. In some cases, PCR products were cloned into the
PCR II vector (Invitrogen, Carlsbad, CA), and at least two
clones were sequenced by using vector-specific primers.
Sequences were aligned by using the Clustal program in
the MacVector (Oxford Molecular Group, Campbell, CA)
software package, and phylogenetic analyses were con-
ducted by using maximum parsimony, neighbor-joining,
and maximum likelihood programs implemented in the
PAUP 4.0 software (22). For the neighbor joining analysis,
the HKY85 distance formula was used. Bootstrap analyses
were conducted with 1,000 replicates to place confidence
values on groupings within trees (23).
Plaque Reduction Neutralization Tests
To obtain immune sera against VEEV subtypes IIIA,
IIIB, IIIC and IIID, cotton rats (Sigmodon hispidus,
Harlan, Indianapolis, IN) were infected subcutaneously
with 1,000 PFUs of virus. Three weeks after injection, the
animals were bled for antibody testing using plaque reduc-
tion neutralization tests (PRNT) with Vero cells (24).
Viruses were tested against all antibody preparations, and
the endpoint titers were defined as the reciprocal of the
Endemic Venezuelan Equine Encephalitis in Northern Peru
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Table 3. Oligonucleotides used for polymerase chain reaction 
amplification and sequencing analysis 
Primer (genetic sense)  Sequence (5′→3′) 
V8369(+)  GAGAACTGCGAGCAATGGTCA 





V8953(–)  CTGCCTACAGGATTAAAT 





Mlu-T25 (–)  TTACGAATTCACGCGTTTTTTTTTTTTTT
TTTTTTTTTTT 
 highest dilution inhibiting >80% of approximately 100
PFU of virus.
Results
Distribution and Characterization of 
Human VEEV Cases in Iquitos
Studies to identify the cause of human febrile illness in
the Amazon region of Peru since 1995 (Watts et al., unpub.
data) identified at least 183 cases of VEEV on the basis of
immunoglobulin (Ig) M antibody detection, virus isola-
tion, or both. The VEEV cases in the Iquitos area were
localized into two major clusters: the region surrounding
Lake Morona Cocha, which typically floods during the
rainy season, and cases near the Itaya and the Amazon
rivers (Figure 2). Cases were also observed to the north
and southwest of Iquitos. Most patients with VEEV did not
report travel outside their home region, suggesting that
many infections occurred in the city of Iquitos. Common
signs and symptoms of VEEV infection included fever,
headache, chills, malaise, diarrhea, vomiting, arthralgia,
and abdominal pain. Clinical information obtained by
NMRCD provided no indication of neurologic disease, and
no deaths were reported. 
Sequencing and Phylogenetic Analysis
An 856-bp fragment from the N terminus of the PE2
gene was obtained for most of the VEEV subtype ID iso-
lates using primers V8369(+)/V9207(–). This region was
chosen because it has been used previously in similar phy-
logenetic analyses, resulting in a large database that allows
for genetic comparison with new isolates (4,9,25). In addi-
tion, the fragment sequenced contains the N-terminal por-
tion of the E2 glycoprotein gene, which has been shown to
undergo critical amino acid substitutions associated with
epizootic VEEV emergence (18). 
To screen the amplified isolates for genetic differences
and to eliminate the cost and effort in sequencing each
virus isolate, SSCP analyses were performed as previously
described (19). At least 2–3 representatives of each SSCP
genotype were selected at random for sequence and phylo-
genetic analysis. Some isolates could not be amplified with
primers V8369(+)/V9207B(–), and later phylogenetic
analyses indicated that they corresponded mainly to sub-
types other than ID. For these isolates, primer V9257(–)
was substituted for V9207B(–) in the cDNAsyntheses and
PCR amplifications. In addition, alphavirus consensus
primers (20) that amplify a portion of the nsP1 gene were
used to confirm the identity of these isolates and to look
for evidence of recombination within the VEE complex
(data not shown). 
Phylogenetic analyses performed using maximum par-
simony, neighbor-joining, and distance-matrix methods
generated similar tree topologies. The neighbor-joining
tree based on the PE2 gene (Figure 3) showed that the
newly sequenced VEEVPeruvian strains grouped into four
major clades: the subtype ID Colombia/Venezuela geno-
type, the ID Panama/Peru genotype, subtype IIIC isolated
in 1971 in the Iquitos area of Peru from a mosquito, and a
newly identified group of viruses that fell within subtype
III but were distinct from IIIC, which we propose as a new
genetic subtype IIID. 
The greatest number of human isolates from Peru fell
into VEEV subtype ID. In agreement with previous studies
(9), genetic analysis of the ID strains delineated two dis-
tinct genotypes that differ by approximately 5% in their
nucleotide sequences: the Colombia/Venezuela genotype,
which is believed to have generated the epizootic IAB and
IC viruses (15–18), and the Panama/Peru genotype. The
Colombia/Venezuela ID genotype was represented by iso-
lates in Peru during the 1970s and two isolates made from
Pantoja in 1994. Previous data suggested that this geno-
type was no longer circulating in Iquitos and had been
replaced by the Panama genotype; however, the evidence
that these viruses continued to circulate in Iquitos was sup-
ported by human isolates from 1998 and 2002, which
grouped into the Colombia/Venezuela clade with strong
RESEARCH
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Figure 2. Map of Iquitos showing the locations of human
Venezuelan equine encephalitis virus cases in the city.bootstrap support (Figure 3). However, most of the
Peruvian VEEV isolates from the Iquitos region grouped
into the ID Panama/Peru genotype and were obtained from
humans, rodents, and mosquitoes. 
The VEE complex subtype IIIC strain, first isolated in
1971 from mosquitoes collected near Iquitos (12,13), was
isolated again in 2002 from a sentinel hamster in the
Amazon region. Several other isolates from mosquitoes,
humans, and rodents also grouped into subtype III (88%
bootstrap support) but were quite distinct from the subtype
IIIC isolates (18% nucleotide sequence, 8% amino acid
sequence divergence in the PE2 protein genes). These lev-
els of divergence are equal to or greater than those of other
VEE complex antigenic subtypes, so we propose the des-
ignation of subtype IIID for these strains. 
To further document these relationships within subtype
III and to investigate possible recombination, phylogenet-
ic trees on the basis of the nsP1 gene were also construct-
ed. The nsP1 trees did not show any evidence of
recombination and also supported the sister-group relation-
ship between subtype IIIC and the related IIID isolates
(data not shown). To further genetically characterize this
new subtype III strains, trees based on the complete 26S
structural gene sequences were generated. All trees,
including the neighbor-joining tree shown in Figure 4,
confirmed the close relationship between the IIIC and IIID
subtypes, as well as their level of divergence. 
Antigenic Characterization of Proposed Subtype IIID
To characterize antigenically the putative new VEEV
subtype IIID, PRNTs were performed to determine the
antigenic relationships among the subtype III viruses
(Table 4). Mucambo virus (subtype IIIA) versus Tonate
virus (subtype IIIB) showed a fourfold difference in only
one direction, which, based on the traditional serologic
classification criteria (26), indicates that these are virus
subtypes. When subtype IIIC was compared with the IIIA
and IIIB subtypes, a fourfold or greater difference was
observed in both directions, indicating that IIIC is a differ-
ent virus. However, only a twofold difference existed in
endpoint titers between subtype IIIC and the new IIID,
which indicated that they are not distinct subtypes accord-
ing to traditional antigenic criteria (28). 
Discussion
VEEV is considered an emerging human pathogen in
Latin America because a resurgence of VEE disease has
occurred in Mexico and South America during the past
decade (8). Our results indicate that VEEV is also endem-
ic in Peru, with cases occurring regularly in the Iquitos
area from 1993 through 2002. Analysis of a larger number
of VEEV isolates allowed us to generate a more accurate
and complete description of VEE complex circulating in
the Amazon Basin of Peru than was possible previously
(9). Most human isolates belong to subtype ID, and phylo-
genetic analyses distinguish two distinct ID genotypes: the
Colombia/Venezuela genotype, which is currently circulat-
ing in Peru, contrary to previous suggestions (9), and the
Panama/Peru genotype, which represents most human iso-
lates. Several hypotheses explain the apparently higher
rate of human infection in the Iquitos area by the ID
Panama/Peru genotype: 1) viruses from the
Colombia/Venezuela genotype are not transmitted effi-
ciently to humans compared to those in the Panama-Peru
genotype; 2) the Panama/Peru genotype circulates at high-
er levels in urban areas such as Iquitos, resulting in more
infections; 3) the Panama/Peru genotype causes more
severe disease, with more patients visiting clinics and par-
ticipating in the NMRCD febrile illness study, resulting in
more virus isolations and; 4) the Panama/Peru genotype
produces higher titer human viremia, resulting in more
human isolates. Further ecologic, epidemiologic, and ento-
mologic studies are needed to test these hypotheses. The
mosquito vector(s) that transmit VEEV to humans in Peru
are unknown. VEEV has been isolated from Culex
(Melanoconion) spp. mosquitoes in Peru, known vectors
Endemic Venezuelan Equine Encephalitis in Northern Peru
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Figure 3. Phylogenetic tree of the Venezuelan equine encephalitis
virus (VEEV) complex derived from partial PE2 gene sequences of
Peruvian VEEV isolates and homologous sequences published
previously, using the neighbor joining program implemented in
PAUP 4.0 (22). The tree was rooted using an outgroup comprised
of four major lineages of Eastern Equine Encephalitis virus (26).
Virus strains are labeled by VEE complex subtype, abbreviated
country (FL=Florida, USA) and year of isolation, followed by strain
designation. Numbers indicate bootstrap values for clades to the
right.of enzootic VEEV in many other locations. Several differ-
ent species (Culex [Mel.] gnomatos, Cx. [Mel.] pedroi, Cx.
[Mel.] vomerifer, and Psorophora albigenu) are competent
laboratory vectors of the ID viruses currently circulating in
the Iquitos area (29,30). Further studies are required to
determine whether these mosquitoes, other species, or both
transmit VEEV to humans in Peru. This information will
be important in understanding human exposure and infec-
tion with these different VEE complex strains. 
Epidemiologic information available from 1995
through 2002 suggests that many VEE cases occurred
within the city of Iquitos. Interviews indicated that many
patients had not traveled during the time of probable infec-
tion, suggesting urban transmission. Studies carried out in
other VEEV-enzootic areas indicate that transmission is
confined to rural and forest habitats (30–32). Whether the
viruses have adapted to infect peridomestic mosquitoes or
whether Amazonian deforestation and urbanization is
increasing the risk for VEEV transmission to humans
through changes in Cx. Melanoconion spp. host preference
and larval habitats remains to be determined.
Subtype III VEE Complex Strains
Before the strain reported herein, the only isolate of
subtype IIIC was obtained in 1971 from a pool of mosqui-
toes collected near Iquitos (12,13). Although epidemiolog-
ic and ecologic studies were conducted in the same area
between 1971 and 1995, no evidence was obtained that the
IIIC virus was still circulating in the Peruvian Amazon
until we isolated it from a sentinel hamster in 2002. The
2002 IIIC isolate did not produce fatal disease in the sen-
tinel animal nor in other hamsters infected experimentally
in our laboratory (data not shown). The failure to isolate
the subtype IIIC virus from febrile patients in Iquitos sug-
gests that it is not transmitted readily to humans, that the
viremia generated in humans is relatively low and usually
undetectable by virus isolation, or that the virus simply
does not cause clinical human disease.
We propose that the newly identified subtype III strain
be defined as a new genetic variety: subtype III, variety D
in the VEE complex. These strains do not represent a new
antigenic subtype (28) because they exhibit a twofold dif-
ference in homologous versus heterologous PRNT anti-
body titers when compared to the IIIC strain. Arbovirus
varieties are described as “isolates differentiable only by
the application of special tests or reagents [kinetic hemag-
glutination inhibition (HI), monoclonal antibody assays,
etc.] (28).” We propose that this definition of special tests
for variety assignment be extended to include sequence
and phylogenetic differentiation of major lineages, such as
IIIC versus the proposed IIID genetic variety. These line-
ages are equivalent in genetic divergence to other VEEV
varieties defined previously based on serologic reactions
using kinetic HI (8,33). 
Both subtype III variants isolated in the Iquitos area are
antigenically distinct from Mucambo (IIIA) and Tonate
(IIIB) viruses, based on greater than fourfold endpoint
antibody titer differences in both directions. The variants
are also quite distinct genetically from Mucambo and
Tonate viruses (23% nucleotide and 14% amino acid
sequence divergence in the structural protein genes) and
appear to be geographically distinct as well. We do not
have enough information available to know whether the
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Figure 4. Unrooted phylogenetic tree of the Venezuelan equine
encephalitis virus (VEEV) complex and other representative
alphaviruses derived from complete structural polyprotein
sequences using the neighbor joining program implemented in
PAUP 4.0 (22). Viruses are labeled by species according to the
International Committee for Taxonomy of Viruses (27). VEEV sub-
type IIIC and IIID strain names are in parentheses. Numbers indi-
cate bootstrap values for clades to the right.
Table 4. Results of the plaque reduction neutralization tests between members of Venezuelan equine encephalitis subtype III
a 
  Antiserum (subtype/variety) 
Virus strain (subtype/variety)  Mucambo (IIIA)  Tonate (IIIB)  71D1252 (IIIC)  PE407660 (IIID) 
Mucambo (IIIA)  1  2  16  8 
Tonate (IIIB)  4  1  >160  8 
71D1252 (IIIC)  >32  4  1  2 
PE4.07660 (IIID)  8  16  2  1 
aNumbers indicate ratios of homologous to heterologous reciprocal titers. IIIA, IIIB, IIIC, and IIID variants share vectors or reser-
voir hosts, although IIIA, IIIC, and IIID probably infect
Proechimys spp., and Tonate virus (IIIB) may use birds as
its reservoir hosts (34). 
The newly identified subtype IIID strain was isolated
from spiny rats (Proechimys spp.), Culex (Melanoconion)
spp. mosquitoes and from a patient with fever, chills, and
malaise. The symptoms are typical of human VEEV (sub-
type I) infection. Using diagnoses based on virus isolation
and serology, Watts et al. (4,14) previously reported that
VEEV was responsible for at least 3% of febrile illnesses
in the city of Iquitos in the Amazon basin of Peru. Subtype
ID was thought to be the cause of these human VEEV
cases, including those diagnosed only by serologic find-
ings. However, our study demonstrated that both VEEV
subtype ID and the newly recognized subtype IIID are
responsible for human illness in the Peruvian Amazon
basin. Whether subtype IIID was responsible for any other
of the 183 human cases diagnosed serologically in Peru
since 1995 is unclear. More detailed studies to retrospec-
tively examine serum samples from these cases are
required to evaluate this possibility. 
Human Disease and Virulence of 
Enzootic VEEV Strains
In Peru, human VEE does not appear to result in neuro-
logic manifestations, and fatal human disease has never
been reported. In contrast, during recent VEEV epidemics
with subtype IC strains in Colombia and Venezuela, an
estimated 3,000 cases with neurologic complications and
300 fatal cases (5,35) were reported. Overall, human death
rates have generally been estimated at approximately 0.5%
during these epidemics, with most of the neurologic dis-
ease and fatal cases reported in children. Most of the
human VEEV cases we studied in Peru occurred in adults
(94.6%), which suggests an occupational exposure or pos-
sibly an age-biased recruitment into the NMRCD febrile
illness study. The lack of any evidence for neurologic dis-
ease in any of the NMRCD cases studied from 1994 to
2003 (D. Watts, unpub. data) suggests a possible difference
in virulence compared with epizootic IAB and IC strains.
Because we characterized only 183 VEEV cases, and only
10 of these were children, whether a virulence difference
exists between enzootic subtype ID and epizootic VEEV
strains is impossible to determine with any statistical cer-
tainty. Strains of the Panama-Peru genotype of subtype ID
are known to have caused fatal human disease (10).
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